Search for other works by this author on: ...

Adding the PD-1 inhibitor pembrolizumab to chemoradiotherapy for high-risk, locally advanced cervical cancer significantly improves patients’ overall survival compared to treatment with CRT alone.

Department of Oral and Maxillofacial Surgery, The Affiliated Stomatological Hospital of Nanjing Medical University, Nanjing, People’s Republic of China.

Cancer Discovery publishes high-impact articles featuring major advances in research and clinical trials. Topics span the spectrum of cancer research and medicine from the laboratory to the clinic to ...

University of Nebraska Medical Center, Omaha, NE, ...

According to the phase IIIb/IV DESTINYBreast-12 Trial, the results of which were presented at the European Society for Medical Oncology 2024 Congress in Barcelona, Spain, and concurrently published, ...

Which manuscripts qualify for the simultaneous publication opportunity? Any manuscripts on the same topic as the author’s submitted abstract, and that are submitted by the deadlines noted below, will ...

This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license. This work is licensed under a Creative Commons ...

Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain.

UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania.

Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

The FDA approved the PD1 inhibitor atezolizumab plus hyaluronidase (Tecentriq Hybreza; Genentech), which helps the drug move into tissues, as a subcutaneous injection for the same adult indications as ...